Article Figures & Data
Figures
- Figure 1
- Progression-free survival of the insulin resistance group and non-insulin resistance group. PFS: progression-free survival, IR: insulin resistance, non-IR: non-insulin resistance
- Figure 2
- Overall survival of the insulin resistance group and non-insulin resistance group. OS: overall survival, IR: insulin resistance, non-IR: non-insulin resistance
Tables
- Table 1
- Clinical characteristics and univariate analysis of 32 patients with diffuse large B-cell lymphoma of the breast.
Variables All (n=32) 5 years progression-free survival 5 years overall survival Precentages P-values Precentages P-values Age at diagnosis 59.13±13.27 ≥60 years 18 (56.3) 81% 0.629 81% 0.738 <60 years 14 (43.7) 55% 63% Gender Male 1 (3.1) -- -- -- -- Female 31 (96.9) Primary site Left 14 (43.8) 69% 0.171 68% 0.129 Right 16 (50.0) 80% 82% Bilateral 2 (6.2) 50% 50% Tumor size 4.15±2.64 ≥5 cm 13 (40.6) 74% 0.129 72% 0.172 <5 cm 19 (59.4) 66% 67% Ann-Arbor stage III-IV 13 (40.6) 61% 0.047* 61% 0.031* I-II 19 (59.4) 75% 71% IPI score 3-5 score 26 (81.2) 67% 0.445 67% 0.360 0-2 score 6 (18.8) 71% 72% B symptoms Yes 7 (21.9) 52% 0.084 52% 0.026* No 25 (78.1) 78% 79% Pathological diagnosis GCB 7 (21.9) 100% 0.164 100% 0.110 Non-GCB 25 (78.1) 64% 60% Metastasis Yes 20 (62.5) 64% 0.235 62% 0.204 No 12 (37.5) 88% 89% Recurrence Yes 11 (34.4) 30% <0.001* 40% 0.001* No 21 (65.6) 100% 100% Outcome Alive 26 (81.3) -- -- -- -- Die 6 (18.7) Comorbidities Yes 25 (78.1) 69% 0.468 69% 0.457 No 7 (21.9) 73% 73% Insulin (uU/ml) 10.54±6.10 -- -- -- -- FPG (mmol/L) 5.93±2.50 -- -- -- -- HOMA-IR 2.45±0.74 >2.7 18 (56.2) 63% 0.864 66% 0.885 ≤2.7 14 (43.8) 78% 79% Values are presented as numbers and prescentages (%).
↵* P-value of <0.05 was significant. IPI: international prognostic index, GCB: germinal center B-cell, FPG: fasting plasma glucose, HOMA-IR: homeostasis model assessment of insulin resistance
- Table 2
- Multivariate analysis of prognostic factors for progression-free survival and overall survival in 32 patients with diffuse large B-cell lymphoma of the breast
Factors Progression-free survival Overall survival HR 95% CI P-values HR 95%CI P-values Ann Arbor stage (III-IV, I-II) 2.18 0.20-23.33 0.519 3.75 0.39-36.15 0.25 B symptoms (Yes, No) 3.34 0.55-20.46 0.19 3.60 0.54-24.08 0.19 Recurrence (Yes, No) 10.99 1.16-104.37 0.037* 7.59 0.87-66.13 0.066 ↵* P-value of <0.05 was significant. HR: hazard ratio, CI: confidence interval
- Table 3
- Immunohistochemistry in 32 patients with primary diffuse large B-cell lymphoma of the breast.
Immunohistochemistry All 5 years progression-free survival 5 years overall survival Precentages P-values Precentages P-values Ki-67 ≥90% 8 (25.0) 85% 0.714 86% 0.670 <90% 24 (75.0) 69% 68% BCL-2 Positive 24 (75.0) 74% 0.455 72% 0.629 Negative 8 (25.0) 73% 75% BCL-6 Positive 21 (65.6) 89% 0.072 90% 0.107 Negative 11 (34.4) 42% 50% C-MYC Positive 25 (78.1) 18% 0.001* 29% 0.004* Negative 7 (21.9) 48% 48% CD79 Positive 7 (21.9) 69% 0.438 71% 0.583 Negative 25 (78.1) 73% 70% PAX-5 Positive 10 (31.2) 26% 0.001* 18% 0.001* Negative 22 (68.8) 94% 95% MUM1 Positive 29 (90.6) 73% 0.617 73% 0.547 Negative 3 (9.4) 67% 67% CD5 Positive 5 (15.6) 100% 0.279 100% 0.228 Negative 27 (84.4) 68% 66% Values are presented as numbers and prescentages (%).
↵* Significant (p<0.05).
- Table 4
- The treatment of patients with primary diffuse large B-cell lymphoma of the breast (N=32).
Treatments All 5 years progression-free survival 5 years overall survival Precentages P-values Precentages P-values Mastectomy No 22 (68.8) 59% 0.917 60% 0.984 Yes 10 (31.2) 77% 79% Chemotherapy Yes 30 (93.8) -- -- -- -- No 2 (6.2) Cycles of chemotherapy ≥4cycles 28 (87.5) 67% 0.303 68% 0.301 <4cycles 4 (12.5) 100% 100% Radiotherapy Yes 8 (25.0) 69% 0.321 73% 0.593 No 24 (75.0) 75% 72% Intrathecal therapy Yes 8 (25.0) 85% 0.699 86% 0.703 No 24 (75.0) 69% 70% Transplantation Yes 2 (6.2) -- -- -- -- No 30 (93.8) Responses CR 21 (65.6) 95% 0.007* 95% 0.015* PR 3 (9.4) 33% 33% SD 0 (0.0) -- -- PD 8 (25.0) 32% 54% Values are presented as numbers and prescentages (%).
↵* Significant (p<0.05). CR: complete remission, PR: partial remission, SD: stable disease, PD: patients progressive disease
In this issue
Jump to section
Related Articles
Cited By...
- No citing articles found.